| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/03/2009 | US20090221602 Processes for preparing substituted pyrimidines |
| 09/03/2009 | US20090221580 Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
| 09/03/2009 | US20090221569 Use of lhrh antagonists for intermittent treatments |
| 09/03/2009 | US20090221547 Immunosuppressant Compounds and Compositions |
| 09/03/2009 | US20090221546 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| 09/03/2009 | US20090221543 New corticosteroids |
| 09/03/2009 | US20090221522 Methods to correct gene set expression profiles to drug sensitivity |
| 09/03/2009 | US20090221519 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
| 09/03/2009 | US20090221508 Immunomodulatory and anti-tumour peptides |
| 09/03/2009 | US20090221506 Gdnf derived peptides |
| 09/03/2009 | US20090221488 Certain Compositions and Methods of Treatment |
| 09/03/2009 | US20090221487 Polyethlene glycol modifications of thymosin alpha-1 |
| 09/03/2009 | US20090221476 Peptide Capable of Altering Tubulin Polymerization and use Thereof for Inhibiting Cell Proliferation |
| 09/03/2009 | US20090221474 Histone deacetylases, and uses related thereto |
| 09/03/2009 | US20090221473 Antitumor agents |
| 09/03/2009 | US20090221077 Process for producing cytotoxic lymphocytes |
| 09/03/2009 | US20090221036 Recombinant anti-cd4 antibodies for human therapy |
| 09/03/2009 | US20090220626 Grape seed extract and its constituents for use as cyp2a6 inhibitors |
| 09/03/2009 | US20090220589 Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas |
| 09/03/2009 | US20090220588 Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity |
| 09/03/2009 | US20090220586 Proteomimetic compounds as inhibitors of the interaction of nuclear receptor with coactivator peptides |
| 09/03/2009 | US20090220554 Transglutaminase Inhibitors and Methods of Use Thereof |
| 09/03/2009 | US20090220551 Concurrent chemotherapy and immunotherapy |
| 09/03/2009 | US20090220527 Affinity optimized epha2 agonistic antibodies and methods of use thereof |
| 09/03/2009 | US20090220512 Genes and polypeptides relating to prostate cancers |
| 09/03/2009 | US20090220510 Recognize aberrant glycosylated form of the EGFR; evident upon aberrant post-translational modification; cancer |
| 09/03/2009 | US20090220509 Singlec-9 binding agents |
| 09/03/2009 | US20090220504 Combinatorial therapy |
| 09/03/2009 | US20090220503 Method for treating cancers with increased ras signaling |
| 09/03/2009 | US20090220502 B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS |
| 09/03/2009 | US20090220498 Method for Discovering Inhibitors of the Epstein-Barr Virus-Induced Gene 3 (EBI3) and Derivatives Thereof for the Treatment of Metastasizing Tumors and Allergic Asthma |
| 09/03/2009 | US20090220495 Cancer Related Genes (PRLR) |
| 09/03/2009 | US20090220493 Reagents and methods for inducing an immune response to prostate specific antigen |
| 09/03/2009 | US20090220486 Antibodies and uses thereof |
| 09/03/2009 | US20090220485 Method for isolation of soluble polypeptides |
| 09/03/2009 | US20090220478 Pharmaceutical active substance |
| 09/03/2009 | US20090220464 Mesenchymal stem cells and uses therefor |
| 09/03/2009 | US20090220461 Metastasis inhibition preparations and methods |
| 09/03/2009 | US20090220460 Virus strains |
| 09/03/2009 | US20090220459 Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof |
| 09/03/2009 | US20090220452 Method Of Producing A Modified (POLY) Peptide |
| 09/03/2009 | US20090220433 Novel biotinylated compositions |
| 09/03/2009 | US20090220427 Drug Resistance and Methods of Reversing |
| 09/03/2009 | DE202009004878U1 Ingwer-Zusammensetzungen Ginger compositions |
| 09/03/2009 | CA2717060A1 Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors |
| 09/03/2009 | CA2717036A1 Methods for prognosing the status of tumor patients |
| 09/03/2009 | CA2717034A1 Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease |
| 09/03/2009 | CA2717026A1 Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof |
| 09/03/2009 | CA2717011A1 Quinolines as inhibitors of farnesyl pyrophosphate synthase |
| 09/03/2009 | CA2716773A1 Fused heterocyclic derivative and use thereof |
| 09/03/2009 | CA2716755A1 Protein kinase modulators |
| 09/03/2009 | CA2716622A1 Glycopeptides and methods of making and using them |
| 09/03/2009 | CA2716499A1 Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-a]pyrimidines, methods for preparation and uses thereof |
| 09/03/2009 | CA2715349A1 Inhibitors of cell proliferation and uses thereof |
| 09/03/2009 | CA2714942A1 Stabilized single-liquid pharmaceutical composition containing docetaxel |
| 09/03/2009 | CA2710962A1 Derivatives of 2-heteroaroyl-imidazol[1,2-a]pyridine, preparation thereef and therapeutic application thereof |
| 09/03/2009 | CA2710947A1 Derivatives of 6-heterocyclic-imidazo[1,2-a]pyrroine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 09/03/2009 | CA2710943A1 Derivatives of n-phenyl-imidazo[1,2-.alpha.]pyridine-2-carboxamides, preon thereof and therapeutic application thereof |
| 09/03/2009 | CA2710860A1 Derivatives of n-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 09/03/2009 | CA2710794A1 Derivatives of n-heterocyclic-6-heterocyclic-imidazo[l,2-.alpha.]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 09/03/2009 | CA2709863A1 Azetidine derivatives, their preparation and their application in therapy |
| 09/02/2009 | EP2096438A1 Methods for prognosing the status of patients |
| 09/02/2009 | EP2096167A1 Aptamer against midkine and use thereof |
| 09/02/2009 | EP2096122A1 Anti-human dlk-1 antibody showing anti-tumor activity in vivo |
| 09/02/2009 | EP2096113A1 9-substituted camptothecin derivatives as antitumor compounds |
| 09/02/2009 | EP2096107A1 Derivatives of squaric acid with anti-proliferative activity |
| 09/02/2009 | EP2095826A1 Nerve elongation promoter and elongation inhibitor |
| 09/02/2009 | EP2095821A1 Anticancer agent |
| 09/02/2009 | EP2094715A2 Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon |
| 09/02/2009 | EP2094713A1 Epothilone analogues modified at positions c12-c13 as anticancer drugs |
| 09/02/2009 | EP2094707A1 Heterobicyclic matrix metalloprotease inhibitors |
| 09/02/2009 | EP2094704A2 Cis-cyclohexyl substituted pyrimidinone derivatives |
| 09/02/2009 | EP2094701A2 Compounds and methods for kinase modulation, and indications therefor |
| 09/02/2009 | EP2094700A2 Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
| 09/02/2009 | EP2094699A2 New imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular cdc7 |
| 09/02/2009 | EP2094698A1 Substituted 6-phenyl-pyrido [2,3-d]pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same |
| 09/02/2009 | EP2094682A2 Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| 09/02/2009 | EP2094681A1 Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors |
| 09/02/2009 | EP2094673A1 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
| 09/02/2009 | EP2094309A2 Alpha-lactalbumin composition |
| 09/02/2009 | EP2094293A1 Tissue targeted antigenic activation of the immune response to treat cancers |
| 09/02/2009 | EP2094291A1 Dimeric prolactin receptor ligands |
| 09/02/2009 | EP2094278A1 Use of lipid containing particles comprising quillaja saponins for the treatment of cancer |
| 09/02/2009 | EP2094268A2 Drug combinations with substituted diaryl ureas for the treatment of cancer |
| 09/02/2009 | EP2094255A1 Modulators of beta-2-adrenergic receptor for treating conditions characterized by disorganized vasculature |
| 09/02/2009 | EP1902037B1 2,4-diamino-pyrimidines used as aurora inhibitors |
| 09/02/2009 | EP1692097B1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods |
| 09/02/2009 | EP1620056B1 Tumor cytotoxicity induced by modulators of the cxcr4 receptor |
| 09/02/2009 | EP1601325B1 Antisense oligonucleotides that inhibit expression of hif-1 |
| 09/02/2009 | EP1481056B1 Modified human manganese superoxide dismutase and uses therof |
| 09/02/2009 | EP1478365B1 Combination consisting of trapidil and 5ht2-serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis |
| 09/02/2009 | EP1472259B1 Tetrapyrrolic macrocycles as photodynamic agents |
| 09/02/2009 | EP1470137B1 Edg receptor agonists |
| 09/02/2009 | EP1458392B1 Acridones as inhibitors of impdh enzyme |
| 09/02/2009 | EP1423115B9 Antiangiogenic activity of nitrogen substituted thalidomide analogs |
| 09/02/2009 | EP1392349B1 Use of angiotensinogen and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions |
| 09/02/2009 | EP1282617B1 Hydantoin derivatives with affinity for somatostatin receptors |
| 09/02/2009 | EP1282443B1 Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| 09/02/2009 | EP1276483B1 Compositions and methods for treating amyloidosis using sulphonate derivatives |
| 09/02/2009 | EP1189645B1 Non-covalent bioconjugates useful for diagnosis and therapy |